Neuro-Oncology · 2023 · 34 citations · 19 references
MedicineOncologyPharmacologyMetabolic RegulationMolecular OncologyTumor MicroenvironmentDiabetes MellitusGlioblastomaGlycemic ControlInsulin ResistanceKetogenic Diet TherapyTumor Microenvironment ModulationGlioblastoma Drug TherapyGlioblastoma Therapeutic ResistanceInsulin Feedback RegulationInsulin Receptor SignalingInsulin Secretion FeedbackPhosphoinositide 3-Kinase PathwayPi3k InhibitorsPi3k Signaling
BACKGROUND: Insulin feedback is a critical mechanism responsible for the poor clinical efficacy of phosphatidylinositol 3-kinase (PI3K) inhibition in cancer, and hyperglycemia is an independent factor associated with poor prognosis in glioblastoma (GBM). We investigated combination anti-hyperglycemic therapy in a mouse model of GBM and evaluated the association of glycemic control in clinical trial data from patients with GBM. METHODS: The effect of the anti-hyperglycemic regimens, metformin and the ketogenic diet, was evaluated in combination with PI3K inhibition in patient-derived GBM cells and in an orthotopic GBM mouse model. Insulin feedback and the immune microenvironment were retrospectively evaluated in blood and tumor tissue from a Phase 2 clinical trial of buparlisib in patients with recurrent GBM. RESULTS: We found that PI3K inhibition induces hyperglycemia and hyperinsulinemia in mice and that combining metformin with PI3K inhibition improves the treatment efficacy in an orthotopic GBM xenograft model. Through examination of clinical trial data, we found that hyperglycemia was an independent factor associated with poor progression-free survival in patients with GBM. We also found that PI3K inhibition increased insulin receptor activation and T-cell and microglia abundance in tumor tissue from these patients. CONCLUSION: Reducing insulin feedback improves the efficacy of PI3K inhibition in GBM in mice, and hyperglycemia worsens progression-free survival in patients with GBM treated with PI3K inhibition. These findings indicate that hyperglycemia is a critical resistance mechanism associated with PI3K inhibition in GBM and that anti-hyperglycemic therapy may enhance PI3K inhibitor efficacy in GBM patients.
19
Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Fabrice André, Eva Ciruelos, Gábor Rubovszky et al. · New England Journal of Medicine · 2019 · 2.6K citations · Full text
Medicine, Oncology, Pharmacology +17
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
David A. Reardon, Alba A. Brandes, Antonio Omuro et al. · JAMA Oncology · 2020 · 1.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Jong‐Ho Cha, Wenhao Yang, Weiya Xia et al. · Molecular Cell · 2018 · 758 citations
Medicine, Immunology, Oncology +14
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Benjamin D. Hopkins, Chantal Pauli, Xing Du et al. · Nature · 2018 · 713 citations · Full text